Dianthus director granted 6,090 stock options
Dianthus Therapeutics director Simon Read reported a grant of 6,090 stock options.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Dianthus Therapeutics director Simon Read reported a grant of 6,090 stock options. These options give him the right to buy 6,090 shares of common stock at an exercise price of 89.63 per share and expire on May 21, 2036.
The award will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholders’ meeting, as long as he continues serving the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Insider Trade Summary
Grant/Award: 6,090 shares
Grant/Award
1 txn
Insider
Read Simon
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,090 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,090 contracts (Direct)
Footnotes (1)
- F1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Key Figures
Options granted: 6,090 options
Exercise price: 89.63 per share
Underlying shares: 6,090 shares
+2 more
5 metrics
Options granted
6,090 options
Stock option award to director on May 21, 2026
Exercise price
89.63 per share
Exercise price of granted stock options
Underlying shares
6,090 shares
Common stock underlying the options
Expiration date
May 21, 2036
Options expire if not exercised by this date
Post-grant derivative holdings
6,090 options
Total derivative position following this transaction
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 89.6300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-05-21T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"award will vest in full on the earlier of the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting of Stockholders financial
"the Issuer's 2027 Annual Meeting of Stockholders, subject to service"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dianthus Therapeutics (DNTH) director Simon Read report on this Form 4?
Director Simon Read reported receiving a grant of 6,090 stock options. These options are a compensation-related award, not an open-market trade, and give him the right to buy Dianthus Therapeutics common stock if and when the options vest and are exercised.
How many Dianthus Therapeutics (DNTH) stock options were granted and what do they cover?
The filing shows a grant of 6,090 stock options. Each option is a right to buy one share of Dianthus Therapeutics common stock, so the award covers 6,090 underlying shares if fully vested and exercised under the terms of the grant.
When do Simon Read’s Dianthus (DNTH) stock options vest?
The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholders’ meeting. Vesting is conditional on Simon Read’s continued service to Dianthus Therapeutics through that vesting date, according to the footnote.
What is the exercise price and expiration date of the Dianthus (DNTH) options?
The stock options have an exercise price of 89.63 per share and an expiration date of May 21, 2036. After expiration, any unexercised options become worthless, so potential value depends on future stock price and timely exercise once vested.
Does this Dianthus (DNTH) Form 4 indicate insider buying or selling in the market?
This Form 4 reports a grant of stock options as compensation, not a market buy or sell. No open-market purchases or sales are disclosed; instead, the company awarded options that may be exercised in the future once vested, at the stated exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
